| Literature DB >> 27388006 |
Dong Sup Lee1, Hyun-Sop Choe1, Hee Youn Kim1, Sun Wook Kim2, Sang Rak Bae3, Byung Il Yoon4, Seung-Ju Lee5.
Abstract
BACKGROUND: The purpose of this study was to identify risk factors for abscess formation in acute bacterial prostatitis, and to compare treatment outcomes between abscess group and non-abscess group.Entities:
Keywords: Abscess; Prostate; Prostatitis; Transurethral resection of prostate
Mesh:
Year: 2016 PMID: 27388006 PMCID: PMC4936164 DOI: 10.1186/s12894-016-0153-7
Source DB: PubMed Journal: BMC Urol ISSN: 1471-2490 Impact factor: 2.264
Demographic characteristics in 142 acute febrile prostatic infections
| With abscess ( | Without abscess ( | Statistical results | |
|---|---|---|---|
| Underlying factors | |||
| Age (years)† | 62.23 ± 14.60 | 63.99 ± 14.27 | 0.546, 2.913, −7.524 ~ 3.994 |
| BMI (Kg/m2)† | 23.93 ± 4.04 | 24.05 ± 3.79 | 0.887, 0.827, −1.756 ~ 1.521 |
| PSA (ng/ml)† | 15.95 ± 11.46 | 20.76 ± 19.17 | 0.200, 3.730, −12.181 ~ 2.571 |
| Prostate size (cc)† | 47.73 ± 19.25 | 40.80 ± 17.53 | 0.063, 3.694, −0.377 ~ 14.242 |
| Abscess size (mm) | 22.03 ± 11.69 | NA | |
| <10 mm: 4; 10 ~ 20 mm: 12; 20 ~ 30 mm: 8; >30 mm: 7 | |||
| Other abscess foci | 4; 2 liver abscesses, 1 renal abscess, 1 buttock abscess | 2; 1 liver abscess, 1 renal abscess | NA |
| Symptom duration† | 7.81 ± 5.42 | 3.04 ± 2.57 | <0.001, 0.691, 3.404 ~ 6.136 |
| Underlying diseases | |||
| Diabetes mellitus‡ | 16/31 | 32/111 | 0.030, 2.633, 1.165 ~ 5.951 |
| Hypertension‡ | 11/31 | 49/111 | 0.418, 0.696, 0.305 ~ 1.589 |
| Heart disease‡ | 4/31 | 23/104 | 0.316, 0.522, 0.166 ~ 1.644 |
| Neurological deficit‡ | 10/31 | 31/111 | 0.658, 1.229, 0.520 ~ 2.903 |
| Chronic kidney disease* | 4/31 | 16/111 | 1.000, 0.880, 0.271 ~ 2.851 |
| Chronic lung disease* | 2/31 | 11/111 | 0.734, 0.627, 0.131 ~ 2.991 |
| Liver cirrhosis* | 7/31 | 15/111 | 0.261, 1.867, 0.685 ~ 5.087 |
| Previous hospitalizations‡ | 8/31 | 16/111 | 0.174, 2.065, 0.788 ~ 5.411 |
| Urological procedures* | 3/31 | 10/111 | 1.000, 1.082, 0.279 ~ 4.201 |
| Long term catheterization* | 2/31 | 12/111 | 0.735, 0.569, 0.120 ~ 2.689 |
| Recent catheterization* | 5/31 | 8/111 | 0.158, 2.476, 0.748 ~ 8.198 |
| Voiding disturbance (Qmax < 5 or PVR > 100)‡ | 15/31 | 15/111 | <0.001, 6.000, 2.464 ~ 14.612 |
| Treatment outcomes | |||
| Septic shock* | 3/31 | 3/111 | 0.118, 3.857, 0.738 ~ 20.152 |
| Death | 1/31 | 1/111 | 0.390, 3.667, 0.223 ~ 60.360 |
| Recurrence | 1/31 | 3/111 | 1.000, 1.189, 0.119 ~ 11.848 |
| Treatment duration† | 40.96 ± 10.61 | 26.98 ± 9.43 | <0.001, 2.111, 9.802 ~ 18.158 |
| With TUR-P ( | 32.31 ± 9.34 | 0.001†† | |
| Without TUR-P ( | 40.85 ± 7.94 | ||
| Admission duration† | 12.38 ± 6.59 | 6.69 ± 2.92 | <0.001, 1.321, 2.978 ~ 8.403 |
| With TUR-P ( | 10.23 ± 2.55 | 0.650†† | |
| Without TUR-P ( | 11.08 ± 9.32 | ||
| Follow-up duration† | 216.0 ± 69.92 | 202.11 ± 59.01 | 0.302, 13.391, −12.602 ~ 40.378 |
†: These continuous values are expressed as means ± standard deviations and student t-tests were performed (statistical data include p-values, standard errors and 95 % confidence intervals, respectively)
‡,*: Statistical evaluation for the nominal parameters was performed using the Chi-squared test‡ or Fisher’s exact test* (statistical data include p-values, odds ratios and 95 % confidence intervals, respectively.)
††: p-values between ‘a’ and ‘b’ were evaluated using the Mann–Whitney U test. Note that all cases (n = 13) treated by TUR-P had abscesses >20 mm in size
Among the 142 cases, 6 cases with metastatic abscesses (1 patient underwent TUR-P) and 2 fatal cases were excluded when comparing the treatment duration, admission duration and follow-up duration
Abbreviations: BMI body mass index; PSA prostate specific antigen; Qmax (ml/sec) maximum urinary flow rate; PVR (ml) post-void residual; TUR-P transurethral resection of prostate
Multivariate analysis of risk factors for abscess formation in acute bacterial prostatitis
|
| OR | 95 % CI | |
|---|---|---|---|
| Voiding disturbance | 0.041 | 2.749 | 1.551 ~ 12.333 |
| Diabetes mellitus | 0.153 | 2.064 | 0.764 ~ 5.575 |
| Symptom duration | <0.001 | 1.343 | 1.166-1.548 |
Statistical analysis was performed using logistic regression test
Fig. 1Abscess drainage with transurethral resection of the prostate
Fig. 2Medical treatment of prostate abscess. a: Before treatment (at diagnosis): an approximately 20-mm-sized abscess was identified in the left lobe of the prostate gland, b: After treatment (follow-up at 4 weeks): a cystostomy catheter was inserted into the urinary bladder. The previous abscess pocket was disappeared
Microorganisms isolated from 142 urinary specimens
| With Abscess | Notes | Without abscess | Notes | |
|---|---|---|---|---|
|
| 7 (26.9) | 1 renal abscess | 71 (74.7) | 1 renal abscess, 1 death |
|
| 6 (23.1) | 1 liver abscess | 8 (8.4) | 1 liver abscess |
|
| 4 (15.4) | 4 (4.2) | ||
|
| 1 (3.8) | 1 (1.1) | ||
|
| 1 (3.8) | 1 (1.1) | ||
|
| 1 (3.8) | 1 Death | 2 (2.1) | |
|
| 0 (0.0) | 1 (1.1) | ||
|
| 1 (3.8) | 1 (1.1) | ||
|
| 0 (0.0) | 1 (1.1) | ||
|
| 0 (0.0) | 1 (1.1) | ||
|
| 3 (11.5) | 1 buttock abscess, 1 squamous cell carcinoma | 1 (1.1) | |
|
| 1 (3.8) | 1 (1.1) | ||
|
| 0 (0.0) | 1 (1.1) | 1 Death | |
| Other GPC | 1 (3.8) | 1 (1.1) | ||
| Positive culture | 26 | 95 | ||
| Negative culture | 5 | 1 Liver abscess | 16 |
The percentage of each microorganism against positive culture is presented in parentheses
Antimicrobial susceptibility of E. coli, K. pneumoniae and P. aeruginosa infections
| With abscess | Without abscess | |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| Amikacin | S 7/7 (100.0) | S 6/6 (100.0) | S 3/4 (75.0) | S 71/71 (100.0) | S 8/8 (100.0) | S 4/4 (100.0) |
| I 0/7 | I 0/6 | I 0/4 | I 0/71 | I 0/8 | I 0/4 | |
| R 0/7 | R 0/6 | R ¼ | R 0/71 | R 0/8 | R 0/4 | |
| Amoxicillin | S 4/7 (57.1) | S 0/6 (0.0) | NA | S 31/71 (43.7) | S 0/8 (0.0) | NA |
| I 0/7 | I 0/6 | I 0/71 | I 0/8 | |||
| R3/7 | R 6/6 | R 40/71 | R 8/8 | |||
| Amoxicillin/clavulanic acid | S 5/7 (71.4) | S 6/6 (100.0) | NA | S 48/71 (67.6) | S 8/8 (100.0) | NA |
| I 2/7 | I 0/6 | I 17/71 | I 0/8 | |||
| R 0/7 | R 0/6 | R 6/71 | R 0/8 | |||
| Aztreonam | S 5/7 (71.4) | S 6/6 (100.0) | S 1/4 (25.0) | S 65/71 (91.5) | S 8/8 (100.0) | S 2/4 (50.0) |
| I 0/7 | I 0/6 | I 1/4 | I 0/74 | I 0/8 | I 1/4 | |
| R 2/7 | R 0/6 | R 2/4 | R 6/74 | R 0/8 | R 1/4 | |
| Cefazolin | S 5/7 (71.4) | S 6/6 (100.0) | NA | S 54/71 (76.1) | S 8/8 (100.0) | NA |
| I 0/7 | I 0/6 | I 0/71 | I 0/8 | |||
| R 2/7 | R 0/6 | R 17/71 | R 0/8 | |||
| Cefepime | S 5/7 (71.4) | S 6/6 (100.0) | S 3/4 (75.0) | S 67/71 (94.4) | S 8/8 (100.0) | S 3/4 (75.0) |
| I 0/7 | I 0/6 | I 0/4 | I 0/71 | I 0/8 | I 1/4 | |
| R 2/7 | R 0/6 | R ¼ | R 4/71 | R 0/8 | R 0/4 | |
| Cefotaxime | S 5/7 (71.4) | S 6/6 (100.0) | S 0/4 (0.0) | S 59/71 (83.1) | S 8/8 (100.0) | S 0/4 (0.0) |
| I 0/7 | I 0/6 | I 0/4 | I 0/71 | I 0/8 | I 0/4 | |
| R 2/7 | R 0/6 | R 4/4 | R 12/71 | R 0/8 | R 4/4 | |
| Cefoxitin | S 7/7 (100.0) | S 6/6 (100.0) | NA | S 68/71 (95.8) | S 8/8 (100.0) | NA |
| I 0/0 | I 0/6 | I 2/71 | I 0/8 | |||
| R 0/0 | R 0/6 | R 1/71 | R 0/8 | |||
| Ceftazidime | S 5/7 (71.4) | S 6/6 (100.0) | S 3/4 (75.0) | S 68/71 (95.8) | S 8/8 (100.0) | S 4/4 (100.0) |
| I 0/7 | I 0/6 | I 0/4 | I 0/74 | I 0/8 | I 0/4 | |
| R 2/7 | R 0/6 | R 1/4 | R 3/71 | R 0/8 | R 0/4 | |
| Ciprofloxacin | S 5/7 (71.4) | S 6/6 (100.0) | S 3/4 (75.0) | S 58/71 (81.7) | S 7/8 (87.5) | S 3/4 (75.0) |
| I 0/7 | I 0/6 | I 0/4 | I 0/71 | I 0/8 | I 0/4 | |
| R 2/7 | R 0/6 | R 1/4 | R 13/71 | R 1/8 | R 1/4 | |
| Imipenem | S 7/7 (100.0) | S 6/6 (100.0) | S 4/4 (100.0) | S 71/71 (100.0) | S 8/8 (100.0) | S 4/4 (100.0) |
| I 0/0 | I 0/6 | I 0/4 | I 0/71 | I 0/8 | I 0/4 | |
| R 0/0 | R 0/6 | R 0/4 | R 0/71 | R 0/8 | R 0/4 | |
| Piperacillin/tazobactam | S 7/7 (100.0) | S 6/6 (100.0) | S 2/4 (50.0) | S 68/71 (95.8) | S 7/8 (87.5) | S 4/4 (100.0) |
| I 0/0 | I 0/6 | I 1/4 | I 1/71 | I 1/8 | I 0/4 | |
| R 0/0 | R 0/6 | R 1/4 | R 2/71 | R 0/8 | R 0/4 | |
| Cotrimoxazole | S 5/7 (71.4) | S 6/6 (100.0) | S 0/4 (0.0) | S 56/71 (78.9) | S 6/8 (75.0) | S 0/4 (0.0) |
| I 0/7 | I 0/6 | I 0/4 | I 0/71 | I 0/8 | I 0/4 | |
| R 2/7 | R 0/6 | R 4/4 | R 15/71 | R 2/8 | R 4/4 | |
Susceptible categories (S/I/R: Sensitive/Intermediate/Resistant)